Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04513665 · OUTCOME

Overall Response Rate/ORR of Participants

ZW25 in Women With Endometrial Cancers · Source last updated 2025-05-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
</= 24 weeks from the start of treatment

What was measured

ORR = Compete Response (CR) + Partial Response (PR) by RECIST v 1.1 \</= 24 weeks from the start of treatment

Analysis population: No participants accrued to Stage 2 arm

Groups in this outcome

Stage 1

Participants will have recurrent endometrial carcinoma or carcinosarcoma with HER2 overexpression and 1-2 prior lines of chemotherapy. 16 participants will be accrued. If 2 or greater responses are seen, Stage 2 will accrue additional participants. ZW25: ZW25 at 20mg/kg intravenously (IV) every two weeks.

Stage 2

If 2 or greater responses are seen during Stage 1, Stage 2 will accrue an additional 9 participants. Participants will have recurrent endometrial carcinoma or carcinosarcoma with HER2 overexpression and 1-2 prior lines of chemotherapy. ZW25: ZW25 at 20mg/kg intravenously (IV) every two weeks.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Stage 116
Stage 20

Reported measurements

Source class 1

Participants with ORR (CR + PR)

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Stage 11Not reportedNot reportedNot reportedNot reported

Participants without ORR (CR + PR)

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Stage 115Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      title
      Participants with ORR (CR + PR)
    2. measurements
      1. group Id
        OG000
        value
        15
      title
      Participants without ORR (CR + PR)
denoms
  1. counts
    1. group Id
      OG000
      value
      16
    2. group Id
      OG001
      value
      0
    units
    Participants
description
ORR = Compete Response (CR) + Partial Response (PR) by RECIST v 1.1 \</= 24 weeks from the start of treatment
groups
  1. description
    Participants will have recurrent endometrial carcinoma or carcinosarcoma with HER2 overexpression and 1-2 prior lines of chemotherapy. 16 participants will be accrued. If 2 or greater responses are seen, Stage 2 will accrue additional participants. ZW25: ZW25 at 20mg/kg intravenously (IV) every two weeks.
    id
    OG000
    title
    Stage 1
  2. description
    If 2 or greater responses are seen during Stage 1, Stage 2 will accrue an additional 9 participants. Participants will have recurrent endometrial carcinoma or carcinosarcoma with HER2 overexpression and 1-2 prior lines of chemotherapy. ZW25: ZW25 at 20mg/kg intravenously (IV) every two weeks.
    id
    OG001
    title
    Stage 2
param Type
COUNT_OF_PARTICIPANTS
population Description
No participants accrued to Stage 2 arm
reporting Status
POSTED
time Frame
</= 24 weeks from the start of treatment
title
Overall Response Rate/ORR of Participants
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice